Procyon Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
Procyon Advisors's LGND Position: Q3 2026 in Review
Procyon Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 39% in Q3 2026, selling an estimated $236K and leaving 1,255 shares worth $392K. The position accounts for 0.02% of the portfolio, ranked #401.
Procyon Advisors first reported a position in LGND in Q2 2026 and has held it in 2 quarters since. The position peaked at $650K in Q2 2026. 348 funds tracked by Wall St. Rank hold LGND as of Q3 2026.
- Procyon Advisors held 1,255 shares of Ligand Pharmaceuticals worth $392K as of Q3 2026.
- Procyon Advisors sold 800 Ligand Pharmaceuticals shares in Q3 2026, an estimated $236K.
- Ligand Pharmaceuticals made up 0.02% of Procyon Advisors's portfolio in Q3 2026, its #401 holding.
- Procyon Advisors first reported a position in Ligand Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
- Procyon Advisors's Ligand Pharmaceuticals position peaked at $650K in Q2 2026.
- 348 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.
Based on Procyon Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.